{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:39:22Z","timestamp":1773113962952,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"DOI":"10.7759\/cureus.104922","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:24:09Z","timestamp":1773069849000},"source":"Crossref","is-referenced-by-count":0,"title":["Epstein-Barr Virus (EBV) Hepatitis Treated With N-Acetylcysteine: Placebo Versus True Effect"],"prefix":"10.7759","author":[{"given":"Ariel","family":"Ahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Abadir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garo","family":"Kalfayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus: biology and clinical disease","volume":"185","author":"Damania B","year":"2022","unstructured":"Damania B, Kenney SC, Raab-Traub N. Epstein-Barr virus: biology and clinical disease. Cell. 2022, 185:3652-70. 10.1016\/j.cell.2022.08.026","journal-title":"Cell"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00211","article-title":"Epstein-Barr virus epidemiology, serology, and genetic variability of LMP-1 oncogene among healthy population: an update","volume":"8","author":"Smatti MK","year":"2018","unstructured":"Smatti MK, Al-Sadeq DW, Ali NH, Pintus G, Abou-Saleh H, Nasrallah GK. Epstein-Barr virus epidemiology, serology, and genetic variability of LMP-1 oncogene among healthy population: an update. Front Oncol. 2018, 8:211. 10.3389\/fonc.2018.00211","journal-title":"Front Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-22822-8_9","article-title":"Infectious mononucleosis","volume":"390","author":"Dunmire SK","year":"2015","unstructured":"Dunmire SK, Hogquist KA, Balfour HH. Infectious mononucleosis. Curr Top Microbiol Immunol. 2015, 390:211-40. 10.1007\/978-3-319-22822-8_9","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/01.smj.0000216469.04854.2a","article-title":"Epstein Barr virus hepatitis: case series and review","volume":"99","author":"Crum NF","year":"2006","unstructured":"Crum NF. Epstein Barr virus hepatitis: case series and review. South Med J. 2006, 99:544-7. 10.1097\/01.smj.0000216469.04854.2a","journal-title":"South Med J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189167","article-title":"N-acetylcysteine (NAC) ameliorates Epstein-Barr virus latent membrane protein 1 induced chronic inflammation","volume":"12","author":"Gao X","year":"2017","unstructured":"Gao X, Lampraki EM, Al-Khalidi S, Qureshi MA, Desai R, Wilson JB. N-acetylcysteine (NAC) ameliorates Epstein-Barr virus latent membrane protein 1 induced chronic inflammation. PLoS One. 2017, 12:e0189167. 10.1371\/journal.pone.0189167","journal-title":"PLoS One"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-020-09049-x","article-title":"Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom","volume":"20","author":"Kuri A","year":"2020","unstructured":"Kuri A, Jacobs BM, Vickaryous N, Pakpoor J, Middeldorp J, Giovannoni G, Dobson R. Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom. BMC Public Health. 2020, 20:912. 10.1186\/s12889-020-09049-x","journal-title":"BMC Public Health"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-019-0954-3","article-title":"Epstein-Barr virus and its association with disease - a review of relevance to general practice","volume":"20","author":"Fugl A","year":"2019","unstructured":"Fugl A, Andersen CL. Epstein-Barr virus and its association with disease - a review of relevance to general practice. BMC Fam Pract. 2019, 20:62. 10.1186\/s12875-019-0954-3","journal-title":"BMC Fam Pract"},{"key":"ref8","article-title":"Epstein-Barr virus infectious mononucleosis","volume":"70","author":"Ebell MH","year":"2004","unstructured":"Ebell MH. Epstein-Barr virus infectious mononucleosis. Am Fam Physician. 2004, 70:1279-87.","journal-title":"Am Fam Physician"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000325","article-title":"Acute liver injury due to severe Epstein-Barr virus infection","volume":"7","author":"Shah J","year":"2020","unstructured":"Shah J, Lingiah V, Pyrsopoulos N, Galan M. Acute liver injury due to severe Epstein-Barr virus infection. ACG Case Rep J. 2020, 7:e00325. 10.14309\/crj.0000000000000325","journal-title":"ACG Case Rep J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2021.0571","article-title":"Role of N-acetylcysteine in non-acetaminophen-related acute liver failure: an updated meta-analysis and systematic review","volume":"34","author":"Walayat S","year":"2021","unstructured":"Walayat S, Shoaib H, Asghar M, Kim M, Dhillon S. Role of N-acetylcysteine in non-acetaminophen-related acute liver failure: an updated meta-analysis and systematic review. Ann Gastroenterol. 2021, 34:235-40. 10.20524\/aog.2021.0571","journal-title":"Ann Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2015.01.003","article-title":"Efficacy and safety of acetylcysteine in \"non-acetaminophen\" acute liver failure: a meta-analysis of prospective clinical trials","volume":"39","author":"Hu J","year":"2015","unstructured":"Hu J, Zhang Q, Ren X, Sun Z, Quan Q. Efficacy and safety of acetylcysteine in \"non-acetaminophen\" acute liver failure: a meta-analysis of prospective clinical trials. Clin Res Hepatol Gastroenterol. 2015, 39:594-9. 10.1016\/j.clinre.2015.01.003","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25551","article-title":"Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011","volume":"55","author":"Lee WM","year":"2012","unstructured":"Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology. 2012, 55:965-7. 10.1002\/hep.25551","journal-title":"Hepatology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/468023-epstein-barr-virus-ebv-hepatitis-treated-with-n-acetylcysteine-placebo-versus-true-effect","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:24:10Z","timestamp":1773069850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/468023-epstein-barr-virus-ebv-hepatitis-treated-with-n-acetylcysteine-placebo-versus-true-effect"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.104922","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}